The Role of NKG2D and Its Ligands in Autoimmune Diseases: New Targets for Immunotherapy
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242417545 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Leiyan Wei und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Basic Medical, Central South University, Changsha 410083, China. Hauptthemen laut MEDLINE: NK Cell Lectin-Like Receptor Subfamily K, Autoimmune Diseases. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: yizhou Zou, National Natural Science Foundation of China.
Abstract (Originalsprache)
Natural killer (NK) cells and CD8+ T cells can clear infected and transformed cells and generate tolerance to themselves, which also prevents autoimmune diseases. Natural killer group 2 member D (NKG2D) is an important activating immune receptor that is expressed on NK cells, CD8+ T cells, γδ T cells, and a very small percentage of CD4+ T cells. In contrast, the NKG2D ligand (NKG2D-L) is generally not expressed on normal cells but is overexpressed under stress. Thus, the inappropriate expression of NKG2D-L leads to the activation of self-reactive effector cells, which can trigger or exacerbate autoimmunity. In this review, we discuss the role of NKG2D and NKG2D-L in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), type I diabetes (T1DM), inflammatory bowel disease (IBD), and celiac disease (CeD). The data suggest that NKG2D and NKG2D-L play a pathogenic role in some autoimmune diseases. Therefore, the development of strategies to block the interaction of NKG2D and NKG2D-L may have therapeutic effects in some autoimmune diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, School of Basic Medical, Central South University, Changsha 410083, China.
ORCID-Profile: Yizhou Zou
Förderung
- yizhou Zou
- National Natural Science Foundation of China
Zitieren
APA
Wei, L., Xiang, Z., & Zou, Y. (2023). The Role of NKG2D and Its Ligands in Autoimmune Diseases: New Targets for Immunotherapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242417545
Vancouver
Wei L, Xiang Z, Zou Y. The Role of NKG2D and Its Ligands in Autoimmune Diseases: New Targets for Immunotherapy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242417545
BibTeX
@article{Wei2023,
author = {Wei, Leiyan and Xiang, Zhiqing and Zou, Yizhou},
title = {The Role of NKG2D and Its Ligands in Autoimmune Diseases: New Targets for Immunotherapy},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242417545}
}
EUVIMED